Today, we announced the launch of AlphaSense for Life Sciences, the single platform for end-to-end life sciences research and competitive intelligence. We’re introducing a suite of clinical trial, regulatory, and reference data with purpose-built tools, combined with AlphaSense’s trusted content and AI.
For life sciences teams, answering a competitive question shouldn't take a week, but it often does. Assessing a therapeutic area today means starting in one database for clinical trial and pipeline data, switching to another for regulatory filings, and then opening AlphaSense in a third tab for the broker research, expert calls, and company documents that explain what any of it means. Every question forces you to manually reconcile the same company, drug, or trial across three or four systems before the real analysis even starts.
AlphaSense changes that. Teams can navigate this data alongside our proprietary and premium content in one workflow and hand off multi-step and monitoring work to SuperAnalyst, our always-on agent. Ask a question — like, “Which companies are running the most Phase 3 trials in a given indication, and what are they telling investors about their approval plans?” — and SuperAnalyst finds the data, builds an interactive dashboard, and gives you back the landscape. The output is grounded in a life sciences knowledge graph that connects clinical trial registries, regulatory approvals, drug labels, patents and exclusivity, and reference data from PubChem, ChEMBL, and MeSH — all standardized and linked across six entity types: company, drug, indication, therapeutic area, target, and mode of action.
Every claim SuperAnalyst makes and every output it produces traces back to the record behind it. Citations link to the source document or the relevant data table, already filtered to show you the exact data behind the claim. In life sciences, that traceability matters: a confident-sounding answer that turns out to be wrong wastes time, sends a competitive assessment in the wrong direction, or makes a recommendation impossible to defend.
From that point on, AlphaSense turns a one-off research project into a standing capability for your team:
- Profile pages break down approved and investigational products, clinical trials, and regulatory filings, with filters for target, mechanism of action, and product type.
- Saved filters carry forward automatically the next time you look at a different company or trial.
- Charts give a visual snapshot of pipelines, approvals, and competitive exposure at a glance.
- Deep linking carries the same logic through the platform — jump from a drug profile to its trials, its filings, or the company behind it, without losing your place.
- One-click CSV export gets the analysis into your model or deck when it's ready.
Coverage isn’t limited to the U.S. and EU. This launch adds ChiCTR, China’s national clinical trial registry, and NMPA drug approvals, so Chinese trials and approvals appear on the same profiles, filters, and citations as their U.S. and EU counterparts.
That’s the shift this launch is built around: research that used to take a week now starts with a defensible answer, already cited and ready to act on. And as the data foundation grows, so does what SuperAnalyst can execute on top of it.
To explore more of what AlphaSense has to offer, sign up for early access to AlphaSense for Life Sciences or start your free trial today.
